GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has submitted a routine compliance certificate to the stock exchanges for the October–December 2025 quarter. The certificate, issued by its Registrar and Share Transfer Agent KFin Technologies, confirms that all share certificates received from depository participants for demat conversion during the quarter were processed and confirmed back to the depositories. It also confirms that physical certificates received for dematerialisation were mutilated and cancelled, and the depository's name was updated in the company's register of members within the 30-day deadline. This is a standard regulatory filing required under SEBI's Depositories Regulations and does not involve any change in capital or ownership.
This is a routine housekeeping compliance filing with no material effect on the company's business, financials, or share price. Shareholders do not need to take any action.